A deep understanding of the unique landscape for combination immuno-oncology (IO) products in France allowed for the development of a set of detailed pricing scenarios
The outputs of this exercise will be taken forwards to develop a full business case for each scenario, which will be used to direct the decision over the launch of the product in France
Inbeeo developed a set of core pricing scenarios, following an extensive landscape review and analogue analysis, to inform the approach to a future IO combination launch.
Inbeeo’s client faced a complex decision framework around the launch of a combination IO product in France. They required support in assessing the potential implications of different future scenarios on both pricing and access, and on planned indication expansions.
HOW WE APPROACHED THE CHALLENGE
Inbeeo performed an extensive review of the IO landscape, identifying several key pricing pressures which could be expected when launching a combination IO product in France.
This was supplemented by analysis of three key analogues, to explore the specific impact of each of these pressures on pricing and access.
This involved an intensive analysis of regulatory timelines and decisions, national and regional HTA decisions, reimbursement, and the funding and coverage status.